Last edition
News about "Phanes Therapeutics"
Phanes Secures Fast Track Designation for PT217 from FDA
PT217, a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47, is being developed for the treatment of patients with small cell lung cancer (SCLC) and neuroendocrine carcinoma, including neuroendocrine prostate cancer (NEPC).
Phanes Therapeutics | 05/12/2024 | By Aishwarya
Phanes PT217 Gets Orphan Drug Designation for Neuroendocrine Carcinoma
PT217 is a first-in-class bispecific antibody targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with NEC.
Phanes Therapeutics | 17/08/2024 | By Aishwarya
Phanes Therapeutics Earns FDA Fast Track Status for Pancreatic Adenocarcinoma Treatment
Phanes Therapeutics has announced that the US Food and Drug Administration has granted Fast Track designation to PT886 for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma.
Phanes Therapeutics | 21/03/2024 | By Manvi | 265
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy